PDS BIOTECHNOLOGY CORP(NASDAQ:PDSB) stock Fundamental Analysis

Fundamental Rating

Overall PDSB gets a fundamental rating of 1 out of 10. We evaluated PDSB against 572 industry peers in the Biotechnology industry. PDSB may be in some trouble as it scores bad on both profitability and health. PDSB does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PDSB has reported negative net income.

PDSB had a negative operating cash flow in the past year.

In the past 5 years PDSB always reported negative net income.

PDSB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -77.32%, PDSB is doing worse than 68.03% of the companies in the same industry.

With a Return On Equity value of -184.34%, PDSB is not doing good in the industry: 68.56% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-77.32%
ROE	-184.34%
ROIC	N/A

ROA(3y)-50.18%

ROA(5y)-49.37%

ROE(3y)-94.65%

ROE(5y)-79.71%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PDSB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, PDSB has more shares outstanding

The number of shares outstanding for PDSB has been increased compared to 5 years ago.

PDSB has a worse debt/assets ratio than last year.

2.2 Solvency

PDSB has an Altman-Z score of -5.36. This is a bad value and indicates that PDSB is not financially healthy and even has some risk of bankruptcy.

PDSB has a Altman-Z score of -5.36. This is in the lower half of the industry: PDSB underperforms 63.94% of its industry peers.

PDSB has a Debt/Equity ratio of 0.55. This is a neutral value indicating PDSB is somewhat dependend on debt financing.

The Debt to Equity ratio of PDSB (0.55) is worse than 76.20% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.55
Debt/FCF	N/A
Altman-Z	-5.36

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.84 indicates that PDSB has no problem at all paying its short term obligations.

With a Current ratio value of 2.84, PDSB is not doing good in the industry: 67.67% of the companies in the same industry are doing better.

PDSB has a Quick Ratio of 2.84. This indicates that PDSB is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 2.84, PDSB is not doing good in the industry: 65.19% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	2.84
Quick Ratio	2.84

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PDSB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.58%, which is quite impressive.

EPS 1Y (TTM)31.58%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%17.14%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -2.07% on average over the next years.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y18%

EPS Next 2Y2.19%

EPS Next 3Y2.61%

EPS Next 5Y-2.07%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PDSB. In the last year negative earnings were reported.

Also next year PDSB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y2.19%

EPS Next 3Y2.61%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PDSB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PDS BIOTECHNOLOGY CORP

NASDAQ:PDSB (2/21/2025, 8:00:00 PM)

After market: 1.35 +0.01 (+0.75%)

1.34

-0.08 (-5.63%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2024-11-14/bmo

Earnings (Next)03-25 2025-03-25/amc

Inst Owners11.4%

Inst Owner Change-2.67%

Ins Owners3.69%

Ins Owner Change0%

Market Cap50.13M

Analysts82

Price Target11.73 (775.37%)

Short Float %11.13%

Short Ratio12.48

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)15.57%

Min EPS beat(2)-2.15%

Max EPS beat(2)33.29%

EPS beat(4)3

Avg EPS beat(4)18.17%

Min EPS beat(4)-2.15%

Max EPS beat(4)33.29%

EPS beat(8)4

Avg EPS beat(8)-5.02%

EPS beat(12)7

Avg EPS beat(12)-2.47%

EPS beat(16)10

Avg EPS beat(16)4.43%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-3.36%

EPS NQ rev (1m)3.15%

EPS NQ rev (3m)5.65%

EPS NY rev (1m)0.75%

EPS NY rev (3m)5.56%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.28
P/tB	2.28
EV/EBITDA	N/A

EPS(TTM)-1.17

EYN/A

EPS(NY)-1.33

Fwd EYN/A

FCF(TTM)-0.94

FCFYN/A

OCF(TTM)-0.94

OCFYN/A

SpS0

BVpS0.59

TBVpS0.59

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-77.32%
ROE	-184.34%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-50.18%

ROA(5y)-49.37%

ROE(3y)-94.65%

ROE(5y)-79.71%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.55
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.84
Quick Ratio	2.84
Altman-Z	-5.36

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)31.58%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%17.14%

EPS Next Y18%

EPS Next 2Y2.19%

EPS Next 3Y2.61%

EPS Next 5Y-2.07%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y23.5%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year12.05%

EBIT Next 3Y-7.05%

EBIT Next 5Y-10.59%

FCF growth 1Y-55.49%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-55.36%

OCF growth 3YN/A

OCF growth 5YN/A

PDS BIOTECHNOLOGY CORP (PDSB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens